10-QPeriod: Q1 FY2024

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q1 Ended Mar 31, 2024

Filed May 7, 2024For Securities:VRTX

Summary

Vertex Pharmaceuticals reported strong financial results for the first quarter of 2024, showcasing significant year-over-year growth in product revenues and a substantial increase in net income. Product revenues rose by 13% to $2.7 billion, driven primarily by the continued strong performance of TRIKAFTA/KAFTRIO in international markets and expanded use in younger age groups in the U.S. This revenue growth, coupled with a strategic decrease in acquired in-process R&D expenses, led to a 46% surge in income from operations and a 57% increase in net income to $1.1 billion. The company's expanding pipeline and recent regulatory approvals, such as CASGEVY for sickle cell disease, highlight its ongoing commitment to innovation and its potential for future growth across multiple therapeutic areas. Financially, Vertex maintains a robust liquidity position with $14.6 billion in cash, cash equivalents, and marketable securities. The company is actively managing its capital, including a substantial share repurchase program and significant investments in R&D. The upcoming acquisition of Alpine Immune Sciences for approximately $4.9 billion underscores Vertex's strategy to bolster its pipeline with promising external assets, particularly in kidney disease. Despite ongoing R&D investments and strategic capital deployment, the company's financial strength and diversified therapeutic focus position it well for continued development and commercial success.

Financial Highlights

47 data points
Beta

Revenue

$2.69B

87.3% Gross Margin

Net Income

$1.10B

40.9% Net Margin

EPS (Diluted)

$4.21

Total Assets

$23.92B

Cash & Equivalents

$9.16B

Free Cash Flow

$1.24B

Financial Statements
Beta
Revenue$2.69B
Cost of Revenue$342.60M
Gross Profit$2.35B
SG&A Expenses$342.70M
Operating Expenses$1.55B
Operating Income$1.14B
Net Income$1.10B
EPS (Basic)$4.26
EPS (Diluted)$4.21
Shares Outstanding (Basic)258.20M
Shares Outstanding (Diluted)261.10M

Key Highlights

  • 1Product revenues increased by 13% to $2.7 billion in Q1 2024, driven by strong TRIKAFTA/KAFTRIO performance.
  • 2Net income grew by 57% to $1.1 billion, or $4.21 per diluted share, reflecting revenue growth and reduced R&D expenses.
  • 3Acquired in-process R&D expenses decreased significantly by 78% to $76.8 million, primarily due to lower upfront and milestone payments.
  • 4CASGEVY, approved for sickle cell disease and beta thalassemia, is progressing with patient initiations and commercial access agreements.
  • 5Preparation for near-term launches of vanzacaftor triple (CF) and suzetrigine (acute pain) are advancing with regulatory submissions.
  • 6Vertex announced plans to acquire Alpine Immune Sciences for $4.9 billion, aiming to strengthen its pipeline in kidney disease.
  • 7The company maintains a strong liquidity position with $14.6 billion in cash, cash equivalents, and marketable securities.

Frequently Asked Questions

The substantial increase in net income was driven by a combination of strong product revenue growth, particularly from TRIKAFTA/KAFTRIO, and a significant reduction in acquired in-process R&D expenses. This improved top-line performance combined with cost efficiencies in R&D led to a higher operating income and consequently, a higher net income.

Vertex is strategically managing its R&D expenses. While total R&D expenses saw a modest increase driven by development costs, acquired in-process R&D expenses decreased dramatically. This suggests a shift in R&D spending, possibly with fewer large upfront or milestone payments for new acquisitions in the current quarter, while continuing investment in ongoing development programs and prioritizing promising pipeline candidates like those for acute pain and type 1 diabetes.

The planned $4.9 billion acquisition of Alpine Immune Sciences is a major strategic move aimed at significantly expanding Vertex's pipeline, particularly in kidney disease. Alpine's lead molecule, povetacicept, shows promise as a potentially best-in-class therapy for IgA nephropathy (IgAN), a significant unmet medical need. This acquisition demonstrates Vertex's commitment to diversifying its portfolio beyond cystic fibrosis and sickle cell disease through external innovation.

Vertex is focused on expanding the reach and impact of its existing therapies. For its cystic fibrosis (CF) franchise, growth is driven by continued uptake in international markets, label expansions into younger age groups, and continued performance in the U.S. For CASGEVY, approved for sickle cell disease and beta thalassemia, the company is focused on activating treatment centers, securing commercial and government reimbursement, and advancing regulatory submissions in new regions. Preparations for near-term launches of new CF and acute pain therapies also underscore this growth strategy.